rs1013724730
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 0P and 6B. BP4_ModerateBS2
The NM_004364.5(CEBPA):āc.364G>Cā(p.Gly122Arg) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000898 in 1,202,562 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Consequence
NM_004364.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -6 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CEBPA | NM_004364.5 | c.364G>C | p.Gly122Arg | missense_variant | 1/1 | ENST00000498907.3 | NP_004355.2 | |
CEBPA | NM_001287424.2 | c.469G>C | p.Gly157Arg | missense_variant | 1/1 | NP_001274353.1 | ||
CEBPA | NM_001287435.2 | c.322G>C | p.Gly108Arg | missense_variant | 1/1 | NP_001274364.1 | ||
CEBPA | NM_001285829.2 | c.7G>C | p.Gly3Arg | missense_variant | 1/1 | NP_001272758.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CEBPA | ENST00000498907.3 | c.364G>C | p.Gly122Arg | missense_variant | 1/1 | NM_004364.5 | ENSP00000427514 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000285 AC: 42AN: 147210Hom.: 0 Cov.: 32
GnomAD4 exome AF: 0.0000625 AC: 66AN: 1055222Hom.: 0 Cov.: 33 AF XY: 0.0000600 AC XY: 30AN XY: 500000
GnomAD4 genome AF: 0.000285 AC: 42AN: 147340Hom.: 0 Cov.: 32 AF XY: 0.000320 AC XY: 23AN XY: 71920
ClinVar
Submissions by phenotype
Acute myeloid leukemia Uncertain:4
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | May 19, 2023 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 01, 2023 | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 122 of the CEBPA protein (p.Gly122Arg). This variant is present in population databases (no rsID available, gnomAD 0.09%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with CEBPA-related conditions. ClinVar contains an entry for this variant (Variation ID: 526801). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CEBPA protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Nov 26, 2019 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Apr 15, 2022 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Aug 17, 2020 | DNA sequence analysis of the CEBPA gene demonstrated a sequence change, c.364G>C, in exon 1 that results in an amino acid change, p.Gly122Arg. This sequence change does not appear to have been previously described in patients with CEBPA-related disorders and has been described in the gnomAD database with a frequency of 0.086% in the African sub-population (dbSNP rs1013724730). The p.Gly122Arg change affects a poorly conserved amino acid residue located in a domain of the CEBPA protein that is known to be functional. The p.Gly122Arg substitution appears to be benign using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to these contrasting evidences and the lack of functional studies, the clinical significance of the p.Gly122Arg change remains unknown at this time. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jul 08, 2022 | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge - |
CEBPA-related disorder Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 13, 2022 | The CEBPA c.364G>C variant is predicted to result in the amino acid substitution p.Gly122Arg. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.086% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/19-33792957-C-G), and it is documented as a variant of uncertain significance by multiple labs in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/526801/evidence/). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Hereditary cancer-predisposing syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | May 30, 2021 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at